WOBURN, Mass. , March 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in December 2022 . “We have been pleased by the positive response to Quell
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced that Frank McGillin , Senior Vice President and General Manager, Consumer will participate in a panel titled "Wearables: Sleeker Smarter Faster" on Thursday, January 7 at 4:30pm (Pacific) at the 2016 CES Event in Las
WOBURN, Mass. , Oct. 06, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has submitted a De Novo request to the U.S. Food and Drug Administration (FDA) for Quell as a prescription treatment for the symptoms of fibromyalgia in adults.
WOBURN, Mass. , Nov. 03, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced the strategic launch of its Quell ® Fibromyalgia device through the Pathfinder Program. Quell Fibromyalgia is the first and only medical device authorized by the U.S.
Joshua S. Horowitz joins Board of Directors At-the-market equity facility terminated WOBURN, Mass. , April 19, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced two steps to enhance shareholder value following feedback and recommendations from one of its largest
BOSTON --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO) reported today that it had shipped its 100,000 th Quell ® wearable device for treatment of chronic pain since commercial launch in mid-2015. Quell device shipments have posted growth in each of the eight sequential quarters that it has
WOBURN, Mass. , July 11, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced expansion of its sales force to drive further adoption of Quell ® Fibromyalgia, which is the first and only medical device authorized by the U.S. Food and Drug Administration (FDA) to help reduce the
WOBURN, Mass. , Feb. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), a commercial stage medical device company focused on reducing the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices, today announced a process to review strategic
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO, NUROW) announced today that the Company's Quell ® Wearable Pain Relief device is now available on Amazon Launchpad. Amazon Launchpad is a program that makes it easy for startups to launch, market, and distribute their products to
